ISCBH HOME

Abstracts

GET IN TOUCH

Whether as an oral communication or a poster, presenting your work at an ICCBH meeting provides you with an opportunity to:

  • Showcase your current work

  • Get support and feedback from others

  • Raise your profile among colleagues internationally and from multiple disciplines

  • Widen your network to open up new opportunities for future collaborations

The full abstract book for ICCBH 2024 is now available in pdf form. Please click the image on the right for access (on your mobile device it will be at the bottom of this page).
 
The abstracts have been published online in JBMR® Plus (Journal of Bone and Mineral Research Plus).  Please click HERE to be re-directed to the page.
 

Abstract Presentation types

Oral communications

As well as dedicated oral communications sessions, there will also be options to present during the symposia.  Orals will generally be 10 minutes (7 for the presentation and 3 for discussion).

Click here for information for Speakers and Presenters

Posters

Posters will be on boards for the entire meeting.  There will be dedicated sessions during each day when presenters will be asked to be at their boards to discuss their data with other delegates.

Click here for information for Printed Poster Presenters 

Call for Abstracts and Challenge the Expert Cases

LATE BREAKING SUBMISSION FOR ICCBH 2024 IS NOW CLOSED.

Thank you to all who submitted during the standard submission period.  Notifications to Late Breaking authors will be sent in the next two weeks.  If you do not receive yours please email the events team on events@theiscbh.org and we can resend it to you.  

The Challenge the Expert submissions is now closed (further information about this is below on this page). 

LATE BREAKING ABSTRACT SUBMISSION CLOSED

Submission Guidelines

For detailed guidelines about submitting your abstract please click HERE.  These are also included in the online submission form.

Abstract Review process

Abstracts containing no data are unlikely to be accepted.  You must include results in your abstract unless you are describing a clinical case.

ICCBH 2024 abstracts are marked under blind conditions by a review panel on the basis of originality, scientific merit and significance.  Reviewers do not score abstracts when there is a potential or actual conflict of interest.  Submitted abstracts are primarily selected for oral/poster presentation on the basis of the scores achieved during the review process.  The Organisers reserve the right to make minimal adjustments to the final programme in order to maintain a breadth and balance of interests in the programme.

Publication

After the conference, abstracts will be published in JBMR® Plus (Journal of Bone and Mineral Research Plus).   

JBMR® Plus is the premier open access journal of the American Society for Bone and Mineral Research (ASBMR). A companion to internationally recognized title Journal of Bone and Mineral Research, JBMR® Plus aims to improve global musculoskeletal health by publishing innovative research covering endocrinology, geriatrics, orthopedics and rheumatology.

Embargo policy

The abstracts will be published on the ICCBH conference website one week before the start of ICBBH 2024.  The abstracts are therefore embargoed until the abstracts have been published.  Posters accepted for ICCBH 2024 are embargoed until the start of the Conference.

Challenge the Expert Cases

Back by Popular Demand for Salzburg 2024!

The Challenge the Expert Session is designed to bring forward challenging cases in the diagnosis and management of children with bone disorders.  The cases should be ones that bring to light key “diagnostic clues” and/or points of “management equipoise” that allow the expert to discuss the nuances of patient care that are not easily gleaned from published articles and textbooks.  

ICCBH Attendees are invited to submit cases by email to the POC via the Events Team  events@theiscbh.org. These should be prepared as powerpoint slides with the following format as a guide:

  • History of presenting illness

  • Relevant medication, past, family and social histories

  • Positive issues identified on review of systems

  • Investigations (as visual as possible, ideally tables with abnormal labs highlighted in red and arrows for directionality, and relevant images [DXA/MRI/CT/bone scans/ultrasounds etc)]*

  • Differential diagnosis

  • Diagnosis

  • Management

  • Discussion points

*The quality of the graphics and images, along with the extent to which a given case will generate discussion, will be used to adjudicate the suitability of cases for this session.

For a given submitted case, the diagnosis and management may not yet be worked out; in other cases, the diagnosis and management may have taken place, but there may be points of equipoise or uncertainty about the current or future management that will generate discussion.

The case can be one that has been accepted to the main meeting as a poster presentation. For any new cases submitted that are not poster presentations, any cases that are NOT selected for the Challenge the Expert Session can be presented as poster presentations if the candidate chooses.

The Expert has 30 minutes to discuss the case, during which time he/she may invite colleagues to also contribute to a certain aspect of the case (eg physiotherapist, geneticist, radiologist). The individual who has submitted the case will also need to be present at the meeting to make comments upon invitation by the Expert. The Expert is asked to discuss the case in a way that is engaging and interactive, including interaction with the case submitter. Two different Experts will discuss two different cases.

Author notifications will be sent following review by the organisers. In case you have any questions please do not hesitate to contact the ICCBH conference team at events@theiscbh.org.

LATE BREAKING ABSTRACT SUBMISSION CLOSED
ISCBH HOME

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

© 2023 International Society for Children’s Bone Health

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE